Related Experiment Video
Updated: Aug 6, 2025

Author Spotlight: Exploring Cytoskeletal Dynamics to Unveil Novel Antibiotics Through Innovative Cell-Based Assays
Published on: April 26, 2024
Homology modeling, virtual screening, molecular docking, and dynamics studies for discovering Staphylococcus
Divya Vemula1, Dhanashri Ramesh Maddi1, Vasundhra Bhandari1
1National Institute of Pharmaceutical Education and Research, Hyderabad, India.
Abstract:
Staphylococcus epidermidis is the most common cause of medical device-associated infections and is an opportunistic biofilm former. Among hospitalized patients, S. epidermidis infections are the most prevalent, and resistant to most antibiotics. In order to overcome this resistance, it is imperative to treat the infection at a cellular level. The present study aims to identify inhibitors of the prokaryotic cell division protein FtsZ a widely conserved component of bacterial cytokinesis. Two substrate binding sites are present on the FtsZ protein; the nucleotide-binding domain and the inter-domain binding sites. Molecular modeling was used to identify potential inhibitors against the binding sites of the FtsZ protein. One hundred thirty-eight chemical entities were virtually screened for the binding sites and revealed ten molecules, each with good binding affinities (docking score range -9.549 to -4.290 kcal/mol) compared to the reference control drug, i.e., Dacomitinib (-4.450 kcal/mol) and PC190723 (-4.694 kcal/mol) at nucleotide and inter-domain binding sites respectively. These top 10 hits were further analyzed for their ADMET properties and molecular dynamics simulations. The Chloro-derivative of GTP, naphthalene-1,3-diyl bis(3,4,5-trihydroxybenzoate), Guanosine triphosphate (GTP), morpholine and methylpiperazine derivative of GTP were identified as the lead molecules for nucleotide binding site whereas for inter-domain binding site, 1-(((amino(iminio)methyl)amino)methyl)-3-(3-(tert-butyl)phenyl)-6,7-dimethoxyisoquinolin-2-ium, and Chlorogenic acidwere identified as lead molecules. Molecular dynamics simulation and post MM/GBSA analysis of the complexes revealed good protein-ligand stability predicting them as potential inhibitors of FtsZ (Figure 1). Thus, identified FtsZ inhibitors are a promising lead compounds for S. epidermidis related infections.
Insights
Researchers identified potential new drugs targeting the FtsZ protein to combat antibiotic-resistant Staphylococcus epidermidis infections. These compounds show promise for treating common medical device-associated infections by inhibiting bacterial cell division.
Area of Science:
- Microbiology
- Biochemistry
- Drug Discovery
Background:
- Staphylococcus epidermidis is a leading cause of medical device infections.
- This opportunistic pathogen frequently forms biofilms and exhibits antibiotic resistance.
- Targeting bacterial cell division offers a novel therapeutic strategy.
Purpose of the Study:
- To identify inhibitors of the prokaryotic cell division protein FtsZ.
- To discover novel compounds effective against Staphylococcus epidermidis infections.
Main Methods:
- Virtual screening of 138 chemical entities against FtsZ binding sites.
- Molecular modeling and docking studies.
- ADMET property analysis and molecular dynamics simulations.
Main Results:
- Ten molecules showed significant binding affinities to FtsZ nucleotide and inter-domain sites.
- Lead compounds identified include GTP derivatives, chlorogenic acid, and isoquinoline derivatives.
- Molecular dynamics simulations confirmed protein-ligand stability.
Conclusions:
- Identified FtsZ inhibitors represent promising lead compounds.
- These compounds offer a potential new avenue for treating S. epidermidis infections.
- Targeting FtsZ provides a strategy to overcome antibiotic resistance.
More Related Videos
05:08Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
10:19Establishment and Optimization of a High Throughput Setup to Study Staphylococcus epidermidis and Mycobacterium marinum Infection as a Model for Drug Discovery
Published on: June 26, 2014